<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Chronic T-Cell | Clinical Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Chronic/Mature T-Cell Leukemia/Lymphoma  Definition: A heterogeneous group of lymphoid neoplasms derived from mature (post-thymic) T lymphocytes or natural killer (NK) cells. These...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Chronic T-Cell | Clinical Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Chronic/Mature T-Cell Leukemia/Lymphoma  Definition: A heterogeneous group of lymphoid neoplasms derived from mature (post-thymic) T lymphocytes or natural killer (NK) cells. These...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Chronic T-Cell | Clinical Hematology">
<meta name="twitter:description" content="Overview of Chronic/Mature T-Cell Leukemia/Lymphoma  Definition: A heterogeneous group of lymphoid neoplasms derived from mature (post-thymic) T lymphocytes or natural killer (NK) cells. These...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Clinical Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="active" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="chronic-t-cell" class="section level1 unnumbered">
<h1>Chronic T-Cell<a class="anchor" aria-label="anchor" href="#chronic-t-cell"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-chronicmature-t-cell-leukemialymphoma" class="section level2 unnumbered">
<h2>
<strong>Overview of Chronic/Mature T-Cell Leukemia/Lymphoma</strong><a class="anchor" aria-label="anchor" href="#overview-of-chronicmature-t-cell-leukemialymphoma"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A heterogeneous group of lymphoid neoplasms derived from mature (post-thymic) T lymphocytes or natural killer (NK) cells. These disorders can present as leukemias (primarily involving the blood and bone marrow) or lymphomas (primarily involving lymph nodes and other tissues)</li>
<li>
<strong>Key Features:</strong>
<ul>
<li>Clonal Proliferation: These are malignant disorders arising from a single, genetically abnormal T cell or NK cell that proliferates uncontrollably</li>
<li>Mature T-Cell Phenotype: The cells express markers characteristic of mature T cells or NK cells (e.g., CD3, CD4, CD8)</li>
<li>Variable Morphology: The cells may have variable size, shape, and nuclear features</li>
<li>Extranodal Involvement: Many of these lymphomas can involve extranodal sites, such as the skin, gastrointestinal tract, and liver</li>
</ul>
</li>
<li>
<strong>Classification:</strong> The World Health Organization (WHO) classification system is used to categorize these disorders based on clinical, morphological, immunophenotypic, and genetic features. T-cell and NK-cell neoplasms can be broadly classified into:
<ul>
<li>T-cell lymphomas</li>
<li>T-cell leukemias</li>
<li>NK-cell lymphomas/leukemias</li>
</ul>
</li>
</ul>
</div>
<div id="key-disorders" class="section level2 unnumbered">
<h2>
<strong>Key Disorders</strong><a class="anchor" aria-label="anchor" href="#key-disorders"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Large Granular Lymphocytic Leukemia (LGL Leukemia):</strong>
<ul>
<li>
<strong>Definition:</strong> A chronic lymphoproliferative disorder characterized by a sustained increase in large granular lymphocytes (LGLs) in the peripheral blood. There are two main subtypes:
<ul>
<li>T-LGL Leukemia: More common; derived from cytotoxic T cells (CD3+, CD8+)</li>
<li>NK-LGL Leukemia: Less common; derived from natural killer cells (CD3-, CD56+)</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Clonal proliferation of LGLs with cytotoxic activity</li>
<li>Associated with STAT3 mutations in many cases</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Often asymptomatic or mild symptoms</li>
<li>Fatigue</li>
<li>Neutropenia: Increased susceptibility to infections</li>
<li>Anemia: Due to pure red cell aplasia (PRCA) or other mechanisms</li>
<li>Splenomegaly (less common)</li>
<li>Association with autoimmune disorders (e.g., rheumatoid arthritis)</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Lymphocytosis with increased LGLs (typically &gt;2.0 x 10^9/L)</li>
<li>Neutropenia</li>
<li>Anemia</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Large granular lymphocytes with abundant cytoplasm and azurophilic granules</li>
</ul>
</li>
<li>Immunophenotyping:
<ul>
<li>T-LGL Leukemia: CD3+, CD8+, CD57+, CD16+, TCRαβ+</li>
<li>NK-LGL Leukemia: CD3-, CD56+, CD16+, CD57+, TCR silent</li>
</ul>
</li>
<li>Bone Marrow Examination:
<ul>
<li>Infiltration of the bone marrow by LGLs</li>
</ul>
</li>
<li>Molecular Testing:
<ul>
<li>
<em>STAT3</em> mutations (in some cases)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Many patients with asymptomatic LGL leukemia do not require treatment</li>
<li>Immunosuppressive Therapy:
<ul>
<li>Methotrexate, cyclosporine, corticosteroids</li>
<li>Used to treat cytopenias and autoimmune manifestations</li>
</ul>
</li>
<li>Cyclophosphamide or fludarabine:
<ul>
<li>May be used in patients with more aggressive disease</li>
</ul>
</li>
<li>Splenectomy:
<ul>
<li>May be considered in patients with symptomatic splenomegaly or cytopenias</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Sézary Syndrome (SS):</strong>
<ul>
<li>
<strong>Definition:</strong> A rare and aggressive form of cutaneous T-cell lymphoma (CTCL) characterized by widespread skin involvement, lymphadenopathy, and the presence of malignant T cells (Sézary cells) in the skin, lymph nodes, and peripheral blood</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Clonal proliferation of malignant CD4+ T helper cells with skin-homing properties</li>
<li>Cells infiltrate the skin, causing erythroderma (generalized redness and scaling of the skin) and plaques</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Erythroderma: Generalized redness and scaling of the skin</li>
<li>Intense Pruritus (itching)</li>
<li>Lymphadenopathy: Swollen lymph nodes</li>
<li>Sézary cells in the skin and peripheral blood</li>
<li>Hepatosplenomegaly (enlarged liver and spleen)</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Leukocytosis with lymphocytosis</li>
<li>Eosinophilia</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Sézary cells: Lymphocytes with cerebriform (brain-like) nuclei</li>
</ul>
</li>
<li>Immunophenotyping:
<ul>
<li>CD3+, CD4+, CD45RO+, CD7- (loss of CD7 is a common finding)</li>
<li>Abnormal T cell receptor expression</li>
</ul>
</li>
<li>Skin Biopsy:
<ul>
<li>Confirms the diagnosis of CTCL and demonstrates the presence of Sézary cells in the skin</li>
</ul>
</li>
<li>T Cell Receptor (TCR) Gene Rearrangement Studies:
<ul>
<li>Demonstrates clonality of the T cell population</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Skin-Directed Therapies:
<ul>
<li>Topical corticosteroids</li>
<li>Phototherapy (PUVA, UVB)</li>
<li>Topical chemotherapy (e.g., mechlorethamine)</li>
</ul>
</li>
<li>Systemic Therapies:
<ul>
<li>Extracorporeal photopheresis (ECP): Treats the blood outside the body with ultraviolet light to kill malignant cells</li>
<li>Interferon-alpha</li>
<li>Histone deacetylase (HDAC) inhibitors (e.g., vorinostat, romidepsin)</li>
<li>Chemotherapy (e.g., CHOP)</li>
<li>Mogamulizumab: An anti-CCR4 monoclonal antibody</li>
</ul>
</li>
<li>Stem Cell Transplantation</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Hodgkin Lymphoma (HL):</strong>
<ul>
<li>
<strong>Definition:</strong> A type of lymphoma characterized by the presence of Reed-Sternberg cells (large, abnormal lymphocytes)</li>
<li>
<strong>Distinction from other lymphomas:</strong> Hodgkin Lymphoma spreads predictably and is more treatable</li>
<li>
<strong>Classical Hodgkin Lymphoma (cHL):</strong> The most common subtype, characterized by the presence of Reed-Sternberg cells and their variants in a background of reactive inflammatory cells. Subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted</li>
<li>
<strong>Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL):</strong> A less common subtype characterized by lymphocyte-predominant Reed-Sternberg cells (L&amp;H cells) and a different immunophenotype</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Arises from germinal center or post-germinal center B cells</li>
<li>Reed-Sternberg cells secrete cytokines that attract and activate other immune cells, leading to the formation of a tumor microenvironment</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Painless Lymphadenopathy: Often in the cervical (neck) or mediastinal (chest) region</li>
<li>B Symptoms: Fever, night sweats, weight loss</li>
<li>Pruritus (itching)</li>
<li>Fatigue</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC: Variable; may be normal or show anemia, leukocytosis, or lymphopenia</li>
<li>Peripheral Blood Smear: Usually normal; may show eosinophilia</li>
<li>Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated</li>
<li>Lymph Node Biopsy: Essential for diagnosis
<ul>
<li>Presence of Reed-Sternberg cells (hallmark of HL)</li>
<li>Immunohistochemistry:
<ul>
<li>Reed-Sternberg cells in cHL: CD30+, CD15+, PAX5+, CD45-</li>
<li>L&amp;H cells in NLPHL: CD20+, BCL6+, CD45+, CD30-, CD15-</li>
</ul>
</li>
</ul>
</li>
<li>Imaging Studies (CT Scan, PET/CT): To stage the disease and assess the extent of involvement</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Chemotherapy:
<ul>
<li>ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)</li>
<li>BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)</li>
</ul>
</li>
<li>Radiation Therapy:
<ul>
<li>May be used in combination with chemotherapy</li>
</ul>
</li>
<li>Brentuximab Vedotin:
<ul>
<li>An anti-CD30 antibody-drug conjugate used for relapsed or refractory HL</li>
</ul>
</li>
<li>Nivolumab and Pembrolizumab:
<ul>
<li>PD-1 inhibitors used for relapsed or refractory HL</li>
</ul>
</li>
<li>Hematopoietic Stem Cell Transplantation (HSCT):
<ul>
<li>May be considered for relapsed or refractory disease</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="important-considerations" class="section level2 unnumbered">
<h2>
<strong>Important Considerations</strong><a class="anchor" aria-label="anchor" href="#important-considerations"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>These are simplified overviews, and many of these disorders have subtypes and variations</li>
<li>Differential diagnosis in this area can be challenging, and often requires integration of clinical, morphological, immunophenotypic, cytogenetic, and molecular data.</li>
<li>Treatment is evolving rapidly, with new targeted therapies and immunotherapies becoming available.</li>
</ul>
</div>
<div id="key-terms-32" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-32"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Lymphoid Neoplasm:</strong> Malignancy originating from lymphocytes</li>
<li>
<strong>T Cells:</strong> Lymphocytes responsible for cell-mediated immunity</li>
<li>
<strong>B Cells:</strong> Lymphocytes responsible for humoral immunity (antibody production)</li>
<li>
<strong>NK Cells:</strong> Large granular lymphocytes involved in innate immunity</li>
<li>
<strong>Lymphoma:</strong> Malignancy primarily involving lymph nodes and other lymphoid tissues</li>
<li>
<strong>Leukemia:</strong> Malignancy primarily involving the bone marrow and peripheral blood</li>
<li>
<strong>Large Granular Lymphocytic Leukemia (LGL Leukemia):</strong> Leukemia of LGLs</li>
<li>
<strong>Sézary Syndrome (SS):</strong> Aggressive cutaneous T-cell lymphoma</li>
<li>
<strong>Hodgkin Lymphoma (HL):</strong> Lymphoma characterized by Reed-Sternberg cells</li>
<li>
<strong>Reed-Sternberg Cells:</strong> Large, abnormal lymphocytes characteristic of Hodgkin lymphoma</li>
<li>
<strong>Immunophenotyping:</strong> Identification of cell surface markers using flow cytometry</li>
<li>
<strong>Cytogenetic Analysis:</strong> The study of chromosomes and their abnormalities</li>
<li>
<strong>Molecular Testing:</strong> Techniques to detect gene mutations and fusion genes</li>
</ul>
</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="chronic-b-cell.html">Chronic B-Cell</a></div>
<div class="next"><a href="plasma-cell.html">Plasma Cell</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#chronic-t-cell">Chronic T-Cell</a></li>
<li><a class="nav-link" href="#overview-of-chronicmature-t-cell-leukemialymphoma">Overview of Chronic/Mature T-Cell Leukemia/Lymphoma</a></li>
<li><a class="nav-link" href="#key-disorders">Key Disorders</a></li>
<li><a class="nav-link" href="#important-considerations">Important Considerations</a></li>
<li><a class="nav-link" href="#key-terms-32">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/master/02-14-leukocyte-neoplasia-lymphoid-chronic-t.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/master/02-14-leukocyte-neoplasia-lymphoid-chronic-t.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-19 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
